Results 181 to 190 of about 181,087 (306)
Chimeric antigen receptor T cell therapy: Revolutionizing cancer treatment. [PDF]
World J Clin OncolArjumand S +4 more
europepmc +1 more source
Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity
Advanced Science, EarlyView.TM4SF1‐nanobody engineered CAR‐natural killer T–derived extracellular vesicles (CARTM4SF1‐EVs) provide a cell‐free alternative to CAR‐NKT therapy, achieving potent, targeted antitumor activity with reduced toxicity. CARTM4SF1‐EVs induce immunogenic cell death, remodel the tumor microenvironment, and enhance CD8⁺ T‐cell antitumor immunity.
Xiaopei Hao +14 more
wiley +1 more source
Discovery of a First‐in‐Class Covalent Allosteric SHP1 Inhibitor with Immunotherapeutic Activity
Angewandte Chemie, EarlyView.A covalent allosteric inhibitor M029 was discovered for SHP1, a novel target for immunotherapy. M029 binds to a cryptic Cys remote from the active site, exhibits robust target engagement, and blocks tumor progression by stimulating antitumor immune response.
Zihan Qu +16 more
wiley +2 more sources
Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases
Advanced Science, EarlyView.This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo +5 more
wiley +1 more source
Programming Next‐Generation Synthetic Biosensors by Genetic Circuit Design
Advanced Science, EarlyView.Synthetic biology enables genetic circuit‐based biosensing to detect diverse targets, process signals, and transduce them into readable outputs or intracellular regulatory activities. However, field deployment and real‐world application of such synthetic biosensors face considerable challenges in sensitivity, specificity, speed, stability, and ...
Yuanli Gao +4 more
wiley +1 more source
Chimeric antigen receptor-based cell therapy for treating urological tumors. [PDF]
Curr UrolTang H, Guo L, Zhang W, Tang D.
europepmc +1 more source
2026 Update on the Management of Diffuse Large B‐Cell Lymphoma
American Journal of Hematology, EarlyView.ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong +2 more
wiley +1 more source
Advanced NanoBiomed Research, EarlyView.Schematic illustration of mTEM8‐loaded cationic liposome (cLipo‐Man/mTEM8) therapeutics for improved triple‐negative breast cancer immunotherapy. Despite triple‐negative breast cancer (TNBC) is the most heterogeneous and aggressive subtype of breast cancer, immunotherapy is emerging as a promising therapy.
Kexin Deng +10 more
wiley +1 more source